• news.cision.com/
  • Attana/
  • Information about Attana's presentation at Redeye Theme: Diagnostics on September 27 at 09.30

Information about Attana's presentation at Redeye Theme: Diagnostics on September 27 at 09.30

Report this content

On Tuesday, September 27 at 09.30 Attana will participate in Redeye’s event, Theme: Diagnostics, where Attana’s CEO, Teodor Aastrup, will give a 12-minute presentation followed by an 8-minute Q&A.

The presentation will begin with a brief description of the company, and then focus on Attana's business how the company's technology can be used within companion diagnostics and to measure the neutralization capacity of e.g., antibodies.

Below is the preliminary agenda for the presentation:

  1. Attana in short
  2. Companion diagnostics
  3. Antibody neutralization capacity
  4. Summary

The event can be viewed online with a Redeye membership. By following the link below, you can find the live broadcast of the presentation and register for a free membership with Redeye.

When: September 27 at 09.30

Where: Digital (Link)

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Subscribe